Mian, Hira http://orcid.org/0000-0003-1584-1067
Sutradhar, Rinku
Pond, Gregory R.
Sivapathasundaram, Branavan
Sussman, Jonathan http://orcid.org/0000-0002-7702-8816
Balitsky, Amaris
D’Souza, Anita http://orcid.org/0000-0002-1092-5643
Wildes, Tanya M.
Seow, Hsien
Article History
Received: 12 October 2021
Revised: 19 December 2021
Accepted: 21 December 2021
First Online: 27 January 2022
Competing interests
: HM: Consultancy/Honoraria fees from Celgene, Takeda, Janssen, Amgen, Sanofi, Research funding Janssen. RS: None. GP: Current hold of individual stocks of Roche Canada. Consultancy fees from Astra-Zeneca, Merck and Profound Medical. Membership on Advisory committee for Takeda. TW: Consultancy fees from Janssen, Carevive, Seattle Genetics, Sanofi. AD: Institutional Research Funding from Sanofi, Takeda, TeneoBio, Caelum, Prothena, Consultancy/Advisory Board fees- Janssen, Prothena, Imbrium, Pfizer, BMS. AB: None. BS: None. JS: None. HS: None.